A Phase 2b, Multicentre, Randomised, Double-blind, Placebo controlled, and Open-label Comparator Study of Cotadutide in Participants Who Have Chronic Kidney Disease with Type 2 Diabetes Mellitus
Latest Information Update: 01 Nov 2023
At a glance
- Drugs Cotadutide (Primary) ; Semaglutide
- Indications Renal failure; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 06 Oct 2023 Primary endpoint (To assess the effects of cotadutide at different dose levels compared to placebo on UACR after 14 weeks) has been met, according to Results presented at the 59th Annual Meeting of the European Association for the Study of Diabetes.
- 06 Oct 2023 Results assessing the effect of cotadutide on both renal and glycaemic endpoints in patients with DKD presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
- 28 Mar 2022 Status changed from active, no longer recruiting to completed.